Zenome: Blockchain-based genomic ecosystem
Zenome is a decentralized market of genomic data and services
Education: Moscow State University, department of molecular biology (MSU)
Degree: Ph.D. in molecular biology and biochemistry
Specialization: Molecular biologist and Blockchain Enthusiast
Specialist in molecular biology and personal genomics. Alexey has a significant scientific background, expertise in business, and project management. In Zenome Alexey is responsible for the overall vision and development of the business.
Education: Moscow Institute of Physics and Technology, department of molecular and biological physics (MIPT)
Degree: Ph.D. in bioinformatics
Specialist in bioinformatics and mathematical biology, has experience of academic research and applied developments in the genome industry. Nikolay is a founder of a company developing new algorithms for genomic analysis.
Genomic data scientist
Education: Pirogov Russian National Research Medical University (RNRMU)
Specialization: Data scientist in human genomics
Bioinformatics and data analysis specialist. ex-CSO at iBinom, bioinformatics scientist at GERO, 8 years in genomics industry. Works on creating pipelines and developing new ways in analysis and visualisations of genomic data.
Education: National Research University "Higher School of Economics", department of Political Science (HSE) – 2017, The University of Edinburgh "School of Social and Political Science" – 2016
Degree: Bachelor in Political Data Analysis
Interests – technology and growth, boxing and foreign languages, humanitarian organizations activity (a volunteer of Russian Red Cross).
Advisor in business development
Education: Moscow State University, department of genetics (MSU)
Degree: Doctoral degree in molecular genetics
Specialization: Businessman and researcher in the field of life sciences
Dr. Nikolsky has 25 years of experience in life sciences, both business and research. Currently, he is CEO of Prosapia Genetics and an associated faculty at George Mason University in Virginia. In 2014-2016, he was CSO/director of Science at the BMT cluster at Skolkovo, the largest innovation fund in Russia. In 2010-2014. Yuri served as Vice President of R&D at Thomson Reuters (TR), a global information company, where he built a scientific consulting group working with major pharmaceutical companies on Big Data management and analysis. In 2003-2010 Dr. Nikolsky was CEO of GeneGo, a systems biology company acquired by Thomson Reuters in 2010. Prior to GeneGo, he was CEO of ChemDiv (San Diego, CA), a drug discovery CRO, turned into a fast growing pharmaceutical company. Dr. Nikolsky also co-founded Integrated Genomics, Inc. (Chicago, IL), a comparative genomics and bioinformatics company and held positions of a Senior Scientist for Thermogen, Inc. (Chicago, IL) and a scientist at the University of Chicago. Dr. Nikolsky holds an MBA degree in finance from the Booth School of Business (the University of Chicago), a Doctoral degree in molecular genetics from VNIIGenetika Graduate School and an MS degree in biology from Lomonosov Moscow State University; both in Moscow, Russia. Dr. Nikolsky’s research interests are in disease research, precision and translational medicine. Dr. Nikolsky authored over 90 research articles, 5 patents and two books on systems biology.
Education: M.B.A. from the MIT Sloan School of Management, an M.S. in Computer Science from Worcester Polytechnic Institute, and a B.S. in Computer Science from the University of Massachusetts at Amherst.
Degree: M.B.A. from the MIT Sloan School of Management
Specialization: Entrepreneur, TED Speaker
Mr. Richard Resnick serves as the Chief Executive Officer of GenomeQuest, Inc. Mr. Resnick served as Acting Chief Executive Officer of GenomeQuest, Inc. since September 2010 and Vice President of Software and Professional Services. Mr. Resnick heads up GenomeQuest's product development and professional services organizations. He served as a Vice President of Products and Services at GenomeQuest, Inc. He served as Vice President of Software & Services at GenomeQuest, Inc. He has extensive experience in building and growing innovative, sales-driven technology teams in the software and life science industries. Prior to joining GenomeQuest, he served as Chief Executive Officer of Harmony Line, Inc. Prior to Harmony Line, he spent over a decade in the sequence informatics industry, founding and selling Mosaic Bioinformatics in 1999 to NetGenics, Inc. He served as global bioinformatics software manager for Wyeth, and contributed to the Human Genome Project under Eric Lander at the MIT Whitehead Institute for Biomedical Research. He serves as a Director of GenomeQuest. Mr. Resnick holds an M.B.A. from the MIT Sloan School of Management, an M.S. in Computer Science from Worcester Polytechnic Institute, and a B.S. in Computer Science from the University of Massachusetts at Amherst.
Education: Moscow State University (MSU), Department of law.
Degree: Bachelor of law (Commercial Law)
Specialization: Corporate law, corporate governance, M&A, venture capital investment
Vadim Pushkarev has 17 years of experience in corporate law and corporate governance. He started his legal career in Professional Association of Registrars, Transfer-Agents and Depositories, self-regulated organization of professional participants of Russian stock market.
In 2002 - 2011 Vadim worked in managerial positions in corporate governance and M&A departments of several Russian industrial companies (including RAO UES of Russia and RusHydro, electric power companies with hundreds of thousands of shareholders and hundreds of subsidiaries). Vadim has an experience of project management in billions-dollar-worth M&A deals, reorganizations and capital stock issuances.
Vadim Pushkarev served as a member of Board of directors in several industrial companies.
In 2011 Vadim made a shift in his career, moving into venture capital industry, and now has an experience of angel, seed, Series A investment deals in different industries and jurisdictions.
In 2014 Vadim was a member of the Board of directors of Sight Diagnostics, Israeli company developing computer-vision based solution for screening blood samples for malaria and CBC (complete blood count test).
Currently Vadim is Associate director at Emery Capital, being responsible for development of several internet-related projects.
Vadim Pushkarev is a member of Board of directors in Accent Media Ltd., London-based company developing new generic top level domain “.tickets” - the new space in Internet, which has already seen several blockchain-based projects, building new technologies for safe and fair ticket sales.
In parallel to his business activities Vadim supports several non-for-profit and charitable activities. Vadim is honored blood donor of Russia.
Cost of the token1 token for 1 $
Price without discounts
Rate the project
Estimate the project on a five-point scale or switch to the simple scale
Estimate the project on a simple scale or switch to the five-point scale
Relevance of the problem and Market size
Founders, Team & Advisors
Budget allocation and roadmap
Token economy, Tokenization & Business model
Distribution & Lock up of tokens, Discounts for early buyers
Summary rate the project